Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
Danese S, Rothenberg ME, Lim JJ, Ding HT, McBride JM, Chen Y, Dash A, Mar JS, Keir M, Peyrin-Biroulet L, Panes J, Colombel JF, Feagan B, Valentine JF, Schreiber S. Danese S, et al. Among authors: ding ht. Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01096-6. doi: 10.1016/j.cgh.2024.11.013. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39694207 Free article.
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc).
Yu Y, Rothenberg ME, Ding HT, Brekkan A, Sperinde G, Harder B, Zhang R, Owen R, Kassir N, Lekkerkerker AN. Yu Y, et al. Among authors: ding ht. J Pharmacokinet Pharmacodyn. 2024 Apr;51(2):141-153. doi: 10.1007/s10928-023-09888-2. Epub 2023 Oct 20. J Pharmacokinet Pharmacodyn. 2024. PMID: 37864000
Comparative Pharmacokinetics and Safety Assessment of 1st- and 2nd-Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study.
Mai TH, Yadav R, Arjomandi A, Jung C, Meier MM, Donaldson F, Zhao R, Ding HT, Hsu JC, Kamath N, Pan L. Mai TH, et al. Among authors: ding ht. Clin Pharmacol Drug Dev. 2024 Jun;13(6):655-664. doi: 10.1002/cpdd.1403. Epub 2024 Apr 23. Clin Pharmacol Drug Dev. 2024. PMID: 38651245 Clinical Trial.
Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Chan P, Ding HT, Liederer BM, Mao J, Belloni P, Chen L, Gao SS, Joseph V, Yang X, Lin JS, Mitra MS, Putnam WS, Quartino A, Bauer RN, Pan L. Chan P, et al. Among authors: ding ht. Clin Transl Sci. 2021 Sep;14(5):1945-1954. doi: 10.1111/cts.13049. Epub 2021 May 31. Clin Transl Sci. 2021. PMID: 34058071 Free PMC article. Clinical Trial.
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Regillo C, et al. Among authors: ding ht. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. Ophthalmology. 2023. PMID: 36870451 Free article. Clinical Trial.
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.
Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, Bravo DD, Chernov-Rogan T, Austin CD, Chen H, Wang L, Villemure E, Shore DGM, Verma VA, Hu B, Chen Y, Leong L, Bjornson C, Hötzel K, Gogineni A, Lee WP, Suto E, Wu X, Liu J, Zhang J, Gandham V, Wang J, Payandeh J, Ciferri C, Estevez A, Arthur CP, Kortmann J, Wong RL, Heredia JE, Doerr J, Jung M, Vander Heiden JA, Roose-Girma M, Tam L, Barck KH, Carano RAD, Ding HT, Brillantes B, Tam C, Yang X, Gao SS, Ly JQ, Liu L, Chen L, Liederer BM, Lin JH, Magnuson S, Chen J, Hackos DH, Elstrott J, Rohou A, Safina BS, Volgraf M, Bauer RN, Riol-Blanco L. Balestrini A, et al. Among authors: ding ht. J Exp Med. 2021 Apr 5;218(4):e20201637. doi: 10.1084/jem.20201637. J Exp Med. 2021. PMID: 33620419 Free PMC article. Clinical Trial.
63 results